<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Scabies: Management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Scabies: Management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Scabies: Management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Beth G Goldstein, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adam O Goldstein, MD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert P Dellavalle, MD, PhD, MSPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Moise L Levy, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ted Rosen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 31, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2138447306"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Scabies is a cutaneous infestation caused by the mite <em>Sarcoptes scabiei </em> (<a class="graphic graphic_picture graphicRef114524 graphicRef114525" href="/d/graphic/114524.html" rel="external">picture 1A-B</a>).</p><p><strong>Classic scabies</strong> is typically characterized by an intensely pruritic eruption with small, often excoriated, papules in sites such as the fingers, wrists, axillae, areolae, waist, genitalia, and buttocks  (<a class="graphic graphic_figure graphicRef71374" href="/d/graphic/71374.html" rel="external">figure 1</a> and <a class="graphic graphic_picture graphicRef51125 graphicRef114527 graphicRef114532 graphicRef76789 graphicRef63974" href="/d/graphic/51125.html" rel="external">picture 2A-E</a>). <strong>Crusted scabies</strong>, a less common clinical variant, typically presents with scaly, crusted, fissured plaques and primarily occurs in immunocompromised individuals  (<a class="graphic graphic_picture graphicRef114538 graphicRef114539 graphicRef114540 graphicRef114541 graphicRef82371" href="/d/graphic/114538.html" rel="external">picture 3A-E</a>). (See  <a class="medical medical_review" href="/d/html/4038.html" rel="external">"Scabies: Epidemiology, clinical features, and diagnosis"</a>.)</p><p>The successful management of scabies involves:</p><p class="bulletIndent1"><span class="glyph">●</span>Eradication of the infestation</p><p class="bulletIndent1"><span class="glyph">●</span>Management of pruritus</p><p class="bulletIndent1"><span class="glyph">●</span>Management of complications</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of close personal contacts</p><p class="bulletIndent1"><span class="glyph">●</span>Implementation of environmental measures to minimize transmission and recurrence of infestation</p><p></p><p>The management of scabies will be reviewed here  (<a class="graphic graphic_algorithm graphicRef134337" href="/d/graphic/134337.html" rel="external">algorithm 1</a>). The clinical manifestations and diagnosis of scabies are discussed separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4038.html" rel="external">"Scabies: Epidemiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H2304417248"><span class="h1">ERADICATION OF INFESTATION</span><span class="headingEndMark"> — </span>The approach to the eradication of scabies mites is dependent upon the clinical presentation (classic or crusted scabies) and patient population  (<a class="graphic graphic_algorithm graphicRef134337" href="/d/graphic/134337.html" rel="external">algorithm 1</a>) (see <a class="local">'Special populations'</a> below). Treatment of both the patient and close personal contacts is suggested to prevent recurrent infestation. (See <a class="local">'Contacts and environment'</a> below.)</p><p class="headingAnchor" id="H3053413688"><span class="h2">Treatment options</span><span class="headingEndMark"> — </span>The availability of antiscabietic agents for classic scabies varies worldwide [<a href="#rid1">1,2</a>]. Topical <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">permethrin</a> and oral <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> are the most common first-line treatments in the United States [<a href="#rid3">3</a>].</p><p>Topical benzyl benzoate (10 or 25%) is commonly used in resource-limited countries because of low cost. Benzyl benzoate is not available in the United States.</p><p>Other therapeutic options include topical sulfur, topical <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a>, topical <a class="drug drug_general" data-topicid="16101" href="/d/drug information/16101.html" rel="external">spinosad</a>, topical <a class="drug drug_general" data-topicid="9301" href="/d/drug information/9301.html" rel="external">crotamiton</a>, and topical <a class="drug drug_general" data-topicid="9562" href="/d/drug information/9562.html" rel="external">lindane</a>. (See <a class="local">'Alternative therapies'</a> below.)</p><p class="headingAnchor" id="H3933536791"><span class="h2">Classic scabies</span><span class="headingEndMark"> — </span>Classic scabies presents as pruritus in association with small, often excoriated papules and burrows  (<a class="graphic graphic_picture graphicRef114527 graphicRef114528 graphicRef114529 graphicRef65362 graphicRef114531 graphicRef114530 graphicRef114532" href="/d/graphic/114527.html" rel="external">picture 2B-C, 2F-J</a>). Prominent scale, crusts, and fissures are absent. (See  <a class="medical medical_review" href="/d/html/4038.html" rel="external">"Scabies: Epidemiology, clinical features, and diagnosis", section on 'Classic scabies'</a>.)</p><p class="headingAnchor" id="H935336014"><span class="h3">Preferred initial therapies</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">Permethrin</a> and <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> are our preferred initial treatments  (<a class="graphic graphic_algorithm graphicRef134337" href="/d/graphic/134337.html" rel="external">algorithm 1</a>). Topical permethrin is highly effective, with cure rates in randomized trials approximating or exceeding 90 percent [<a href="#rid4">4,5</a>]. Oral ivermectin is an alternative first-line treatment that has the advantages of ease of administration and lower cost.</p><p>Special considerations are warranted for young children and pregnant individuals. (See <a class="local">'Special populations'</a> below.)</p><p class="headingAnchor" id="H2911796506"><span class="h4">Permethrin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">Permethrin</a> is a topical synthetic pyrethroid agent that impairs function of voltage-gated sodium channels in insects, leading to disruption of neurotransmission [<a href="#rid6">6</a>].</p><p><a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">Permethrin</a> is considered safe for use in infants as young as two months of age, children, adults, and pregnant or lactating individuals [<a href="#rid7">7</a>] (see <a class="local">'Special populations'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Patients should massage <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">permethrin</a> cream thoroughly into the skin from the neck to the soles of the feet, including areas under the fingernails and toenails [<a href="#rid8">8</a>]. A 30 g tube contains a sufficient quantity for a single application for an average adult.</p><p></p><p class="bulletIndent1">In young children, scalp involvement is common. Therefore, <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">permethrin</a> should also be applied to the scalp and face (sparing the eyes and mouth) in this population.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">Permethrin</a> should be removed by washing (shower or bath) after 8 to 14 hours. Treatment is often performed overnight.</p><p></p><p class="bulletIndent1">A second application one to two weeks later may be necessary to eliminate mites and is typically performed [<a href="#rid6">6,9</a>]. However, the relative efficacy of one versus two applications of <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">permethrin</a> is unclear.</p><p></p><p class="bulletIndent1">Limited data suggest that other regimens may also be effective [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – High-quality trials comparing scabies treatments are limited [<a href="#rid4">4,5</a>]. In a systematic review and meta-analysis of randomized trials, topical <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">permethrin</a> and oral <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> appeared similarly effective [<a href="#rid11">11</a>]. A network meta-analysis of 52 randomized trials that compared a topical or oral intervention for scabies with placebo or another therapy supports a higher cure rate for permethrin compared with other topical therapies, including sulfur, <a class="drug drug_general" data-topicid="9584" href="/d/drug information/9584.html" rel="external">malathion</a>, <a class="drug drug_general" data-topicid="9562" href="/d/drug information/9562.html" rel="external">lindane</a>, <a class="drug drug_general" data-topicid="9301" href="/d/drug information/9301.html" rel="external">crotamiton</a>, and benzoyl benzoate [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">Permethrin</a> is generally well tolerated. Skin irritation is a potential side effect.</p><p></p><p class="headingAnchor" id="H4097880160"><span class="h4">Oral ivermectin</span><span class="headingEndMark"> — </span>Oral <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> is an antiparasitic alternative to <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">permethrin</a> that has the advantage of ease of administration. This mode of treatment may be particularly useful for large scabies outbreaks in nursing homes and other facilities where topical therapy can be impractical. (See <a class="local">'Institutional setting'</a> below.)</p><p>Oral <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> is <strong>not</strong> a recommended first-line treatment for pregnant individuals and children who weigh less than 15 kg because of safety concerns  (<a class="graphic graphic_algorithm graphicRef134337" href="/d/graphic/134337.html" rel="external">algorithm 1</a>) [<a href="#rid7">7</a>] (see <a class="local">'Special populations'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">Ivermectin</a> therapy for classic scabies consists of a 200 mcg/kg single oral dose followed by a repeat dose after one to two weeks [<a href="#rid7">7,13,14</a>]. The second treatment is necessary because ivermectin has limited ovicidal activity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Various studies support the efficacy of oral <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a>. One randomized trial (n = 55) found a higher cure rate at seven days with single-dose ivermectin (200 mcg/kg) than placebo (79 versus 16 percent) [<a href="#rid15">15</a>]. In addition, based upon a systematic review and meta-analysis of randomized trials, oral ivermectin appears to be as effective as topical <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">permethrin</a> [<a href="#rid11">11</a>]. A network meta-analysis supports similar efficacy of oral ivermectin and topical permethrin as well as greater efficacy of oral ivermectin compared with topical <a class="drug drug_general" data-topicid="9584" href="/d/drug information/9584.html" rel="external">malathion</a>, <a class="drug drug_general" data-topicid="9562" href="/d/drug information/9562.html" rel="external">lindane</a>, <a class="drug drug_general" data-topicid="9301" href="/d/drug information/9301.html" rel="external">crotamiton</a>, and benzyl benzoate [<a href="#rid12">12</a>]. (See <a class="local">'Permethrin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Oral <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> is generally well tolerated in patients treated for scabies. Most, but not all, reports of severe adverse effects have occurred in patients with helminthic infections [<a href="#rid16">16-18</a>]. The validity of an isolated report of increased deaths among residents of a nursing home treated with oral ivermectin for scabies has been questioned [<a href="#rid19">19-21</a>]. (See  <a class="medical medical_review" href="/d/html/487.html" rel="external">"Anthelminthic therapies", section on 'Ivermectin'</a>.)</p><p></p><p class="headingAnchor" id="H3657856070"><span class="h3">Alternative therapies</span><span class="headingEndMark"> — </span>Alternative topical therapies for scabies include benzoyl benzoate, sulfur, <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a>, <a class="drug drug_general" data-topicid="16101" href="/d/drug information/16101.html" rel="external">spinosad</a>, <a class="drug drug_general" data-topicid="9301" href="/d/drug information/9301.html" rel="external">crotamiton</a>, <a class="drug drug_general" data-topicid="9584" href="/d/drug information/9584.html" rel="external">malathion</a>, and <a class="drug drug_general" data-topicid="9562" href="/d/drug information/9562.html" rel="external">lindane</a>. These agents have not been shown to be more effective than <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">permethrin</a> [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H2804037317"><span class="h4">Benzyl benzoate</span><span class="headingEndMark"> — </span>Benzyl benzoate is commonly used in resource-limited countries because of the drug's low cost. Benzyl benzoate is not available in the United States:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Treatment regimens vary. Benzyl benzoate may be applied once daily at night on two consecutive days, with a repeat treatment cycle after seven days [<a href="#rid1">1</a>]. Typical treatment concentrations for benzyl benzoate are 25% for adults and 10 or 12.5% for children over the age of one year [<a href="#rid14">14,22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Efficacy data on benzyl benzoate are limited but suggest benefit [<a href="#rid23">23,24</a>]. An open-label trial that randomly assigned children and adults with scabies to either one of two application regimens for 12.5% benzyl benzoate or oral <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a>, followed by repetition of the same treatment on day 7 for patients with worsening symptoms, supports efficacy [<a href="#rid23">23</a>]. Cure at day 14 (disappearance of skin lesions and itching) occurred in 70 percent of patients in whom each treatment with benzyl benzoate consisted of two 24-hour applications separated by 24 hours, in 54 percent of patients in whom each treatment with benzyl benzoate consisted of a single 24-hour application, and in 25 percent of patients treated with 150 to 200 mcg/kg of oral ivermectin. Some limitations of the trial included disproportionate loss to follow-up and early trial cessation due to perceived superior benefit of benzoyl benzoate. In addition, cure rates with ivermectin were lower than reported in other studies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Local skin irritation and pruritus are potential adverse effects [<a href="#rid23">23,24</a>].</p><p></p><p class="headingAnchor" id="H4242034848"><span class="h4">Topical sulfur</span><span class="headingEndMark"> — </span>Topical precipitated sulfur is relatively inexpensive and primarily used for the treatment of neonates and pregnant individuals. The mechanism of action is thought to involve keratolytic effects and scabicidal properties [<a href="#rid25">25</a>] (see <a class="local">'Special populations'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – In the United States, sulfur must be compounded. Concentrations of 2 to 10% are typical. A typical regimen for adults consists of 8 or 10% precipitated sulfur in petrolatum. Lower concentrations (eg, ≤6%) are typically used for infants [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1">Sulfur ointment is applied overnight, rinsed off, and reapplied similarly for three consecutive days. Treatment may be repeated in 7 to 14 days in an attempt to improve efficacy [<a href="#rid25">25</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Data on the efficacy of topical sulfur are limited [<a href="#rid26">26-28</a>]. An open-label trial in which 100 children were treated with either 10% sulfur ointment applied for seven consecutive nights or 0.3% gamma benzene hexachloride gel as a single overnight application repeated after one week found similar efficacy for achieving clinical cure (absence of new lesions and healing of all old lesions in 92 and 91 percent of patients, respectively) and parasitic cure (absence of parasites on skin scraping in 83 and 84 percent of patients, respectively) after four weeks [<a href="#rid27">27</a>]. In an uncontrolled study in which 124 children with scabies residing in orphanages received four applications of either 5 or 10% precipitated sulfur in petrolatum over three consecutive days, 71 percent of the 102 children available for follow-up after four weeks achieved cure (no new lesions, healing of all original active lesions, and negative skin scraping) [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Adverse effects include a burning sensation, skin erythema, and malodor [<a href="#rid26">26,27</a>].</p><p></p><p class="headingAnchor" id="H4263319289"><span class="h4">Topical ivermectin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">Ivermectin</a> 1% lotion has been used for the treatment of scabies. Ivermectin binds to glutamate-gated chloride channels in invertebrate nerve and muscle cells, leading to increased permeability of cell membranes to chloride ions, hyperpolarization of nerve or muscle cells, and paralysis and death [<a href="#rid29">29</a>]. Although other forms of topical ivermectin are available for the treatment of rosacea and head lice, ivermectin 1% lotion is not available in the United States:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">Ivermectin</a> 1% lotion is applied to all body sites from the neck down. The drug is washed off after 8 to 14 hours. Application should be repeated after one week for patients with persistent symptoms [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Topical <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> 1% lotion appears to have efficacy for scabies [<a href="#rid30">30-32</a>]. An open-label, randomized trial (n = 315) that compared <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">permethrin</a> 5% cream, ivermectin 1% lotion, and oral ivermectin (200 mcg/kg) supports efficacy of topical ivermectin [<a href="#rid30">30</a>]. Patients were assessed weekly for four weeks after initial treatment, with repetition of the same treatment up to week 3 if clinical cure (resolution of visible, scabietic lesions but not necessarily pruritus) was not achieved. At the end of the second week after initial treatment, clinical cure rates for permethrin, topical ivermectin, and oral ivermectin were 99, 100, and 63 percent, respectively, and all groups achieved a clinical cure rate of at least 99 percent by the end of the third week. No adverse effects occurred in patients treated with topical ivermectin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Topical <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> appears to be well tolerated. Local skin irritation or burning sensations are potential adverse effects.</p><p></p><p class="headingAnchor" id="H1843969837"><span class="h4">Spinosad</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16101" href="/d/drug information/16101.html" rel="external">Spinosad</a> is a topical agent that causes fatal neuronal excitation in insects. In 2021, the US Food and Drug Administration (FDA) approved spinosad 0.9% topical suspension for the treatment of scabies in adults and children four years of age and older:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – <a class="drug drug_general" data-topicid="16101" href="/d/drug information/16101.html" rel="external">Spinosad</a> 0.9% suspension should be shaken well prior to application [<a href="#rid33">33</a>]. Proper application involves rubbing the product into the skin to completely cover the skin from the neck to the soles of the feet. Patients with a balding scalp should also apply spinosad to the scalp, hairline, forehead, and temples. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="16101" href="/d/drug information/16101.html" rel="external">Spinosad</a> should be allowed to dry on the skin for 10 minutes prior to putting on clothing. The product should be left on the skin for at least six hours before showering or bathing. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – <a class="drug drug_general" data-topicid="16101" href="/d/drug information/16101.html" rel="external">Spinosad</a> has demonstrated efficacy for scabies in two phase 3, placebo-controlled, randomized trials [<a href="#rid34">34</a>]. In the trials, 206 households with a total of 533 adults and children were randomly assigned to a single six- to eight-hour application of spinosad 0.9% topical suspension or vehicle [<a href="#rid34">34</a>]. Efficacy analyses performed for the youngest members of each household at day 28 in the first trial showed complete cure (a combination of clinical and microscopic cure) in 82 of 105 patients (78 percent) in the spinosad group and 40 of 101 patients (40 percent) in the vehicle group.</p><p></p><p class="bulletIndent1">The relative efficacy of <a class="drug drug_general" data-topicid="16101" href="/d/drug information/16101.html" rel="external">spinosad</a> compared with <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">permethrin</a> and oral <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> is unclear.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – <a class="drug drug_general" data-topicid="16101" href="/d/drug information/16101.html" rel="external">Spinosad</a> is generally well tolerated. In the randomized trials, adverse events considered related to spinosad use included burning sensations and dry skin, each occurring in less than 1 percent of patients. </p><p></p><p class="headingAnchor" id="H2887980680"><span class="h4">Other therapies</span><span class="headingEndMark"> — </span>Additional topical treatment options for scabies include <a class="drug drug_general" data-topicid="9301" href="/d/drug information/9301.html" rel="external">crotamiton</a>, <a class="drug drug_general" data-topicid="9584" href="/d/drug information/9584.html" rel="external">malathion</a>, and <a class="drug drug_general" data-topicid="9562" href="/d/drug information/9562.html" rel="external">lindane</a> [<a href="#rid1">1,7</a>]. These therapies appear to be less effective than <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">permethrin</a> and oral <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> [<a href="#rid12">12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Crotamiton</strong> – The treatment regimen for <a class="drug drug_general" data-topicid="9301" href="/d/drug information/9301.html" rel="external">crotamiton</a> is not standardized. The drug can be applied to the entire body from the chin down (including under the fingernails), reapplied 24 hours later, and washed off 48 hours after the last application [<a href="#rid35">35</a>]. Regimens consisting of application for up to five successive days or longer have also been utilized [<a href="#rid2">2</a>]. In randomized trials, crotamiton has appeared less effective than <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">permethrin</a> [<a href="#rid5">5,36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malathion</strong> – A single application of <a class="drug drug_general" data-topicid="9584" href="/d/drug information/9584.html" rel="external">malathion</a> 0.5% lotion is typically performed. Malathion is applied to the skin at night and washed off after 8 to 12 hours [<a href="#rid1">1</a>]. Disadvantages of malathion include flammability of the product and relatively high cost.</p><p></p><p class="bulletIndent1">Data on <a class="drug drug_general" data-topicid="9584" href="/d/drug information/9584.html" rel="external">malathion</a> are limited. In a trial that randomly assigned 340 patients with scabies to two applications of either <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> 1% lotion or malathion 0.5% lotion separated by one week followed by retreatment (if needed), cure rates for ivermectin and malathion were 68 and 44 percent, respectively, at week 2 and 85 and 68 percent, respectively, at four weeks [<a href="#rid31">31</a>]. Case series also suggest efficacy [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lindane</strong> – Use of <a class="drug drug_general" data-topicid="9562" href="/d/drug information/9562.html" rel="external">lindane</a> has fallen out of favor due to risk for systemic toxicity (eg, seizures, death) [<a href="#rid1">1,7</a>]. European and Japanese guidelines recommend <strong>against</strong> use of this therapy [<a href="#rid1">1,2</a>]. Lindane lotion or cream is not available in the United States. (See  <a class="medical medical_review" href="/d/html/4035.html" rel="external">"Pediculosis capitis", section on 'Lindane toxicity'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9562" href="/d/drug information/9562.html" rel="external">Lindane</a> should be used only as an alternative therapy in patients who cannot tolerate other therapies or when other therapies have failed [<a href="#rid7">7</a>]. A thin layer of lindane 1% (1 oz of lotion or 30 g of cream) is applied to all areas of the body from the neck down and thoroughly washed off after eight hours [<a href="#rid7">7</a>].</p><p></p><p class="headingAnchor" id="H3340555677"><span class="h2">Crusted scabies</span><span class="headingEndMark"> — </span>Crusted scabies presents with plaques or papules with overlying, prominent, adherent scale and crusts  (<a class="graphic graphic_picture graphicRef114538 graphicRef114539 graphicRef114540 graphicRef114541 graphicRef82371" href="/d/graphic/114538.html" rel="external">picture 3A-E</a>). Erythema may also be present:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preferred initial therapy</strong> – Combination treatment with <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">permethrin</a> and oral <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> is the preferred first-line treatment for crusted scabies. Treatment with permethrin alone requires repeated applications, and the failure rate is significant. Oral ivermectin combined with topical therapy has appeared effective in case reports and case series [<a href="#rid37">37-40</a>].</p><p></p><p class="bulletIndent1">We agree with the United States Centers for Disease Control and Prevention's combination regimen for the treatment of crusted scabies [<a href="#rid14">14</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">Permethrin</a> 5% cream applied every two to three days for one to two weeks</p><p></p><p class="bulletIndent2"><strong>and</strong></p><p></p><p class="bulletIndent2">Oral <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> (200 mcg/kg/dose) given for three, five, or seven nonconsecutive days depending on severity of infestation (approximately days 1, 2, and 8; approximately days 1, 2, 8, 9, and 15; or approximately days 1, 2, 8, 9, 15, 22, and 29)</p><p></p><p class="bulletIndent1">The application procedure for <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">permethrin</a> is similar to the procedure for classic scabies. (See <a class="local">'Permethrin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other interventions</strong> – Topical benzyl benzoate (25% for adults, 10 or 12.5% for children) is an alternative to <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">permethrin</a> [<a href="#rid1">1,25</a>]. (See <a class="local">'Benzyl benzoate'</a> above.)</p><p></p><p class="bulletIndent1">Concomitant use of topical keratolytic creams (eg, <a class="drug drug_general" data-topicid="10073" href="/d/drug information/10073.html" rel="external">ammonium lactate</a> 12% lotion for the body or urea 10% cream for the hands and feet in adults) may help to reduce crusting [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1">The use of <a class="drug drug_general" data-topicid="9562" href="/d/drug information/9562.html" rel="external">lindane</a> is contraindicated in patients with crusted scabies due to risk for toxicity [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/4035.html" rel="external">"Pediculosis capitis", section on 'Lindane toxicity'</a>.)</p><p></p><p class="headingAnchor" id="H915126748"><span class="h2">Special populations</span></p><p class="headingAnchor" id="H2475940090"><span class="h3">Children</span><span class="headingEndMark"> — </span>Given its high efficacy and safety, <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">permethrin</a> is our preferred therapy for children  (<a class="graphic graphic_algorithm graphicRef134337" href="/d/graphic/134337.html" rel="external">algorithm 1</a>). However, topical sulfur, which is considered safe in infants, is typically used for the treatment of infants under the age of two months because of lack of regulatory approval for permethrin use in infants in this age group. (See <a class="local">'Permethrin'</a> above and <a class="local">'Topical sulfur'</a> above.)</p><p>A survey study documents active use of <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">permethrin</a> for young infants in the clinical setting despite the uncertainty about safety [<a href="#rid41">41</a>]. Among 57 dermatologists (including 48 pediatric dermatologists) who responded to a survey about scabies treatment for infants under the age of two months, 47 (83 percent) reported experience with use of permethrin, and 38 (67 percent) considered permethrin the preferred therapy for infants in this age group.</p><p>Safety data for <a class="drug drug_general" data-topicid="16101" href="/d/drug information/16101.html" rel="external">spinosad</a> are limited to children who are at least four years old. <a class="drug drug_general" data-topicid="9562" href="/d/drug information/9562.html" rel="external">Lindane</a> should not be given to children under the age of 10 years because of risk for systemic toxicity [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/4035.html" rel="external">"Pediculosis capitis", section on 'Lindane toxicity'</a> and <a class="local">'Spinosad'</a> above.)</p><p>Treatment with oral <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> is <strong>not</strong> recommended for children who weigh less than 15 kg [<a href="#rid1">1</a>]. The safety of oral ivermectin has not been determined in this population. Although a retrospective study of the efficacy and tolerability of oral ivermectin for scabies in infants under 15 kg found that 12 of 14 achieved resolution of clinical features of scabies within one month and documented few adverse events [<a href="#rid42">42</a>], additional data are needed before use of this drug in infants with scabies can be recommended. (See <a class="local">'Oral ivermectin'</a> above.)</p><p>Guidance on the use of benzyl benzoate in infants varies. Whereas some sources support safety of a 6.25% concentration for use on infants [<a href="#rid25">25</a>], avoidance in infants has also been recommended [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H480591172"><span class="h3">Pregnant individuals</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">Permethrin</a> is considered safe for use in pregnant and lactating patients and is a preferred treatment  (<a class="graphic graphic_algorithm graphicRef134337" href="/d/graphic/134337.html" rel="external">algorithm 1</a>) [<a href="#rid7">7</a>]. Systemic absorption is low, and the drug is metabolized quickly.</p><p>Second-line treatments for pregnant individuals include topical sulfur and benzyl benzoate [<a href="#rid1">1,43</a>]. Although risk associated with oral <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> may be low, data on use in this population are limited [<a href="#rid7">7</a>]. <a class="drug drug_general" data-topicid="9562" href="/d/drug information/9562.html" rel="external">Lindane</a> is contraindicated in pregnancy [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H135687356"><span class="h1">TREATMENT OF PRURITUS</span><span class="headingEndMark"> — </span>Antihistamines may improve pruritus, which may persist for up to four weeks after successful treatment [<a href="#rid44">44</a>]. We typically prescribe a nonsedating antihistamine (eg, <a class="drug drug_general" data-topicid="9572" href="/d/drug information/9572.html" rel="external">loratadine</a>, <a class="drug drug_general" data-topicid="9236" href="/d/drug information/9236.html" rel="external">cetirizine</a>, <a class="drug drug_general" data-topicid="8445" href="/d/drug information/8445.html" rel="external">fexofenadine</a>) during the day and a sedating antihistamine (eg, <a class="drug drug_general" data-topicid="8544" href="/d/drug information/8544.html" rel="external">hydroxyzine</a>, <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a>) at night. (See  <a class="medical medical_review" href="/d/html/131632.html" rel="external">"Pruritus: Therapies for generalized pruritus", section on 'Role of antihistamines'</a> and  <a class="medical medical_review" href="/d/html/7526.html" rel="external">"Pharmacotherapy of allergic rhinitis", section on 'Oral antihistamines'</a>.)</p><p>After the eradication of mites, medium- or high-potency topical corticosteroids  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 1</a>) can be prescribed to control itching [<a href="#rid45">45</a>]. In severe cases, patients can be treated with an oral glucocorticoid taper over one to two weeks, starting with 40 to 60 mg of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> daily for adults.</p><p>Symptoms should progressively improve with adequate therapy. If symptoms worsen despite adequate treatment, the possibility of re-exposure or an alternative diagnosis should be considered. (See <a class="local">'Recognition of cure and treatment failure'</a> below.)</p><p class="headingAnchor" id="H3485493417"><span class="h1">RECOGNITION OF CURE AND TREATMENT FAILURE</span><span class="headingEndMark"> — </span>The state of pruritus and skin lesions is the primary measure for recognizing likely cure or treatment failure. Reassessment is warranted when these findings persist for more than four to six weeks after the completion of treatment  (<a class="graphic graphic_algorithm graphicRef134337" href="/d/graphic/134337.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Findings consistent with cure</strong> – Therapy is likely successful if active lesions resolve and nocturnal pruritus ceases by one week after treatment [<a href="#rid1">1</a>]. Some pruritus often persists for two to four weeks after successful treatment. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with persistent pruritus or active skin lesions</strong> – Pruritus extending beyond four weeks may indicate persistent infestation or reinfestation. Postscabetic nodules, treatment-related irritant or allergic contact dermatitis, and misdiagnosis are other potential causes of persistent pruritus. (See  <a class="medical medical_review" href="/d/html/4038.html" rel="external">"Scabies: Epidemiology, clinical features, and diagnosis", section on 'Differential diagnosis'</a> and <a class="local">'Nodules'</a> below and  <a class="medical medical_review" href="/d/html/1731.html" rel="external">"Allergic contact dermatitis in children"</a> and  <a class="medical medical_review" href="/d/html/13655.html" rel="external">"Clinical features and diagnosis of allergic contact dermatitis"</a> and  <a class="medical medical_review" href="/d/html/13661.html" rel="external">"Irritant contact dermatitis in adults"</a>.)</p><p></p><p class="bulletIndent1">Mite resistance to the prescribed treatment is considered a rare cause of treatment failure [<a href="#rid25">25</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patient assessment</strong> – The assessment of patients with persistent pruritus or active skin lesions should include a careful history (to ensure correct administration of the prescribed therapy and review symptoms and risk factors for reinfestation) and a physical examination (to assess for findings supportive of persistent scabies or alternative diagnoses). Visual inspection for burrows and performance of a scabies preparation to identify scabies mites, eggs, or feces is helpful for confirming persistent infestation. (See  <a class="medical medical_review" href="/d/html/4038.html" rel="external">"Scabies: Epidemiology, clinical features, and diagnosis", section on 'Examination for mites'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management</strong> – Patients in whom clinical or microscopic findings support persistent infestation require retreatment. The best approach to retreatment has not been established. When <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">permethrin</a> or oral <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> therapy fails and the reason for failure is unclear, we switch to the other therapy (eg, from permethrin to oral ivermectin) or treat with both agents simultaneously. If this intervention fails and persistent scabies is confirmed, we proceed to an alternative antiscabietic therapy (eg, topical sulfur). (See <a class="local">'Alternative therapies'</a> above.)</p><p></p><p class="headingAnchor" id="H2235269785"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Potential complications of scabies include secondary infection and cutaneous nodules.</p><p class="headingAnchor" id="H3370239736"><span class="h2">Secondary infection</span><span class="headingEndMark"> — </span>Secondary bacterial infections should be treated with appropriate systemic antibiotics. Streptococcal infections associated with scabies have resulted in glomerulonephritis [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/d/html/4038.html" rel="external">"Scabies: Epidemiology, clinical features, and diagnosis", section on 'Complications'</a>.)</p><p class="headingAnchor" id="H1890372730"><span class="h2">Nodules</span><span class="headingEndMark"> — </span>Nodules from scabies may persist after the eradication of mites. Dermoscopy may be helpful for identifying patients with residual, active disease [<a href="#rid47">47</a>] (see  <a class="medical medical_review" href="/d/html/4038.html" rel="external">"Scabies: Epidemiology, clinical features, and diagnosis", section on 'Classic scabies'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical or intralesional corticosteroids</strong> – Nodules can be treated with once- or twice-daily application of a potent topical corticosteroid for two to three weeks or intralesional injection of a corticosteroid such as <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide (5 to 10 mg/mL)  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 1</a>) [<a href="#rid48">48</a>]. Intralesional corticosteroid injections may also be useful for nodules that fail to respond adequately to topical corticosteroid therapy. The injection volume should just make the lesion blanch; typically, 0.1 mL per nodule is adequate. Cutaneous atrophy is a potential side effect of topical intralesional corticosteroid therapy. (See  <a class="medical medical_review" href="/d/html/5565.html" rel="external">"Topical corticosteroids: Use and adverse effects", section on 'Adverse effects'</a> and  <a class="medical medical_review" href="/d/html/5568.html" rel="external">"Intralesional corticosteroid injection", section on 'Adverse effects and pitfalls'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other therapies</strong> – Limited data suggest that topical calcineurin inhibitors may be beneficial. Improvement of nodules after treatment with topical <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> 0.03% ointment has been documented in a small case series, and topical <a class="drug drug_general" data-topicid="10162" href="/d/drug information/10162.html" rel="external">pimecrolimus</a> appeared effective in a case report [<a href="#rid49">49,50</a>]. Resolution of nodules following cryotherapy has also been reported [<a href="#rid51">51</a>]. Additional studies are needed to confirm the efficacy of these treatments.</p><p></p><p class="headingAnchor" id="H139851212"><span class="h1">CONTACTS AND ENVIRONMENT</span></p><p class="headingAnchor" id="H3086476845"><span class="h2">Overview</span><span class="headingEndMark"> — </span>The onset of symptoms of scabies is often delayed for several weeks; therefore, close personal contacts may have active scabies even in the absence of symptoms. As a result, simultaneous treatment of cohabitants and individuals with prolonged physical contact is generally practiced to avoid an endless cycle of transmission and reinfestation [<a href="#rid52">52</a>]. However, high-quality, randomized trials to confirm the efficacy of this practice and to determine the best treatment regimen are lacking [<a href="#rid53">53</a>]. Close personal contacts are typically treated with the same regimens used for classic scabies. (See <a class="local">'Classic scabies'</a> above.)</p><p>Environmental measures are suggested with the goal of minimizing risk for transmission or reinfestation. Scabies mites generally do not survive for more than two to three days away from human skin. Therefore, such measures are focused on items and areas in contact with the patient over the preceding several days.</p><p>General environmental measures include laundering or sequestering items that came in close, prolonged contact with the individual who is infested and adequate cleaning of rooms inhabited by patients with crusted scabies. A more aggressive approach is indicated in institutional settings to minimize risk for transmission to other patients and staff [<a href="#rid9">9</a>].</p><p>Fomite transmission is most likely to occur in the setting of crusted scabies, given the associated high mite burden (up to millions of mites). (See  <a class="medical medical_review" href="/d/html/4038.html" rel="external">"Scabies: Epidemiology, clinical features, and diagnosis", section on 'Transmission'</a>.)</p><p>Application of pesticides is <strong>not</strong> indicated in either the home or institutional setting.</p><p class="headingAnchor" id="H1096368278"><span class="h2">Community setting</span><span class="headingEndMark"> — </span>Scabies in the community setting warrants treatment of close contacts and environmental measures:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contacts</strong> – The patient and cohabitants or other individuals who have had prolonged skin-to-skin contact in the preceding six weeks should be treated simultaneously. Because symptoms of scabies may be delayed for up to six weeks in individuals who are newly infested, the absence of symptoms does not confirm the absence of infestation. </p><p></p><p class="bulletIndent1">Ideally, the patient should inform and encourage such contacts to seek medical attention for treatment [<a href="#rid54">54</a>]. Although commonly practiced, treatment of cohabitants without an examination performed by the prescribing clinician is controversial. Local policies regarding the legality of this practice (ie, expedited partner therapy) vary [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Environment</strong> – In addition, items used within the preceding several days (clothing, linens, stuffed animals, etc) can be machine washed and dried using the heat cycle or removed from body contact for at least 72 hours [<a href="#rid7">7</a>]. Dry cleaning is an alternative. Rooms used by patients with crusted scabies should be thoroughly cleaned and vacuumed.</p><p></p><p class="headingAnchor" id="H3169976699"><span class="h2">Institutional setting</span><span class="headingEndMark"> — </span>In the institutional setting, a diagnosis of scabies should trigger heightened awareness to facilitate the identification and treatment of additional individuals with scabies. In the setting of multiple individuals with classic scabies or at least one patient with crusted scabies, the institution should implement an institution-wide education program about scabies. Notification of the local health department is indicated if there is the potential for spread beyond the institution [<a href="#rid9">9</a>].</p><p>The United States Centers for Disease Control and Prevention provides <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fparasites%2Fscabies%2Fhealth_professionals%2Finstitutions.html&amp;token=xDHqh2WsssZzco9pOAyu0E92clUWiiH5TDArmmC8nD9f9wVI5e6npfCpBsYKVWLm6ZBA4pg0QzOL3J0D7cjBHstzkl9Mzsgtu7zGTEf7SR8%3D&amp;TOPIC_ID=114369" target="_blank">detailed recommendations</a> for the management of scabies in institutional settings [<a href="#rid56">56</a>]. Local health departments are another useful resource:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classic scabies</strong> – Suggested general management measures for asymptomatic individuals who are or have been in contact with a patient with <strong>classic</strong> scabies include [<a href="#rid9">9</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adherence to appropriate infection control measures when handling patients (eg, avoidance of direct skin-to-skin contact, use of gloves when providing hands-on care, handwashing after providing care)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment of staff, other patients, and household members who had prolonged skin-to-skin contact with the patient</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Offering of treatment to household members of staff who are receiving treatment for scabies</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Avoidance of skin-to-skin contact with the patient until at least eight hours after treatment</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Laundering of clothing and bedding of the affected patient with a washing machine and dryer utilizing hot water and hot dryer cycles</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Routine cleaning and vacuuming of the room after the patient is discharged from the room</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Crusted scabies</strong> – Rapid identification and treatment of <strong>crusted</strong> scabies is essential to minimize dissemination of the infestation. Institutional infection control personnel should be contacted immediately, and the patient should be isolated from other patients in the institution. Suggested general management measures following a diagnosis of <strong>crusted</strong> scabies include [<a href="#rid9">9</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prompt involvement of institutional infection control personnel.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Isolation of the affected patient from other patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Assignment of a dedicated care team for the patient to minimize exposure of staff, if feasible.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Strict contact precautions, including avoidance of direct skin-to-skin contact with the patient and use of protective gowns, gloves, and shoe covers, until the patient has been treated and a scabies preparation is negative.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Frequent cleaning of the patient's room to remove contaminated scales and crusts; thorough cleaning and vacuuming of the room after the patient is discharged from the room.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Laundering of clothing and bedding with a washing machine and dryer utilizing hot water and hot dryer settings; utilization of protective clothing and gloves by laundry personnel.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment of all individuals (eg, staff, visitors, family members/caregivers) who came in direct physical contact with the patient or clothing, bedding, or furniture.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Offering of treatment to household members of staff who are receiving scabies treatment.</p><p></p><p class="headingAnchor" id="H2418354463"><span class="h2">Endemic scabies</span><span class="headingEndMark"> — </span>Mass drug administration, which involves repeat administration of single doses of therapeutic agents to the entire community, has been shown to be an effective control strategy for scabies in hyperendemic areas [<a href="#rid57">57</a>]. Oral <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> is our preferred intervention given the drug's efficacy and ease of administration:</p><p class="bulletIndent1"><span class="glyph">●</span>The Skin Health Intervention Fiji Trial (SHIFT), involving three island communities with a scabies prevalence &gt;20 percent, compared the efficacy of three approaches: mass administration of a single dose of oral <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> 200 mcg/kg of body weight, mass administration of a single dose of topical <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">permethrin</a>, and standard treatment (topical permethrin treatment only for persons with scabies and their contacts) [<a href="#rid13">13</a>]. Participants with scabies received a second dose of the assigned medication after 7 to 14 days. The primary outcome was the change in the prevalence of scabies and impetigo from baseline to 12 months. At 12 months, the prevalence of scabies had declined by 94 percent in the ivermectin group (95% CI 83-100 percent), 62 percent in the permethrin group (95% CI 49-75 percent), and 49 percent in the standard care group (95% CI 37-60 percent). The prevalence of impetigo was reduced by 67, 54, and 32 percent in the three groups, respectively. Adverse effects were mild but more common in the ivermectin group than in the permethrin group (16 versus 7 percent).</p><p></p><p class="headingAnchor" id="H3983015041"><span class="h1">RETURN TO WORK OR SCHOOL</span><span class="headingEndMark"> — </span>Individuals with classic scabies can return to work, child care, or school the day after the first treatment [<a href="#rid9">9</a>]. This is appropriate provided treatment has been administered correctly and the patient agrees to complete the prescribed course of treatment.</p><p class="headingAnchor" id="H100381289"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115068.html" rel="external">"Society guideline links: Scabies"</a>.)</p><p class="headingAnchor" id="H3204589763"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15464.html" rel="external">"Patient education: Scabies (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/7628.html" rel="external">"Patient education: Scabies (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H272604929"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment overview</strong> – Scabies is a common cutaneous infestation caused by the mite <em>Sarcoptes scabiei</em>. Management involves:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Eradication of the infestation</p><p class="bulletIndent2"><span class="glyph">•</span>Management of pruritus</p><p class="bulletIndent2"><span class="glyph">•</span>Management of complications</p><p class="bulletIndent2"><span class="glyph">•</span>Treatment of close personal contacts</p><p class="bulletIndent2"><span class="glyph">•</span>Implementation of environmental measures to minimize transmission and recurrence of infestation (see <a class="local">'Introduction'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview of antiscabietic therapies </strong>– Scabies may be treated with topical or oral therapies. The major options for topical therapy include <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">permethrin</a> (preferred), benzyl benzoate, precipitated sulfur, <a class="drug drug_general" data-topicid="16101" href="/d/drug information/16101.html" rel="external">spinosad</a>, and <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a>. Use of <a class="drug drug_general" data-topicid="9562" href="/d/drug information/9562.html" rel="external">lindane</a> has fallen out of favor due to risk for systemic toxicity. Oral ivermectin is available for systemic treatment. (See <a class="local">'Treatment options'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of classic scabies</strong> – Classic scabies, the most common presentation of scabies, can be treated with either topical or oral therapy  (<a class="graphic graphic_figure graphicRef71374" href="/d/graphic/71374.html" rel="external">figure 1</a> and <a class="graphic graphic_picture graphicRef51125 graphicRef114527 graphicRef114532 graphicRef76789 graphicRef63974" href="/d/graphic/51125.html" rel="external">picture 2A-E</a> and <a class="graphic graphic_algorithm graphicRef134337" href="/d/graphic/134337.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent1">For patients with classic scabies, we suggest topical <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">permethrin</a> for initial treatment rather than topical benzoyl benzoate, sulfur, <a class="drug drug_general" data-topicid="9301" href="/d/drug information/9301.html" rel="external">crotamiton</a>, <a class="drug drug_general" data-topicid="9584" href="/d/drug information/9584.html" rel="external">malathion</a>, or <a class="drug drug_general" data-topicid="9562" href="/d/drug information/9562.html" rel="external">lindane</a> based upon data that suggest greater efficacy of permethrin (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). High efficacy and safety support the preferred use of permethrin therapy.</p><p></p><p class="bulletIndent1">Oral <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> is an alternative initial treatment for nonpregnant adults who prefer oral treatment, cannot tolerate <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">permethrin</a>, or are unable to apply topical therapy. <a class="drug drug_general" data-topicid="16101" href="/d/drug information/16101.html" rel="external">Spinosad</a> and topical ivermectin are additional options for topical therapy that have not been proven superior to permethrin therapy. (See <a class="local">'Classic scabies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of crusted scabies</strong> – For patients with crusted scabies  (<a class="graphic graphic_picture graphicRef114538 graphicRef114539 graphicRef114540 graphicRef114541 graphicRef82371" href="/d/graphic/114538.html" rel="external">picture 3A-E</a>), we suggest combination therapy with <a class="drug drug_general" data-topicid="9759" href="/d/drug information/9759.html" rel="external">permethrin</a> and <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> rather than either therapy alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The duration of treatment is dependent upon the severity of infestation. (See <a class="local">'Crusted scabies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recognition of cure and treatment failure</strong> – Signs of successful treatment include resolution of active skin lesions and nocturnal pruritus one week after the completion of treatment  (<a class="graphic graphic_algorithm graphicRef134337" href="/d/graphic/134337.html" rel="external">algorithm 1</a>). However, some pruritus often persists for up to four weeks after successful treatment. Examples of causes of pruritus beyond this period include treatment failure, treatment-related skin irritation or contact dermatitis, reinfestation, and misdiagnosis. (See <a class="local">'Recognition of cure and treatment failure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Close contacts</strong> – The onset of symptoms may be delayed for several weeks after infestation. Thus, asymptomatic individuals who have been in close personal contact with a patient with classic scabies may have active scabies. Patients with confirmed scabies and close contacts should be treated simultaneously. (See <a class="local">'Contacts and environment'</a> above and <a class="local">'Community setting'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Environmental measures</strong> – Scabies mites typically cannot survive for more than two to three days when separated from human skin. Clothing or bedding items used within the preceding three days by the individual who is infested should be machine washed with hot water and machine dried with a heat cycle. Dry cleaning items or removing items from body contact for at least 72 hours is an alternative. Rooms used by individuals with crusted scabies should be cleaned and vacuumed. (See <a class="local">'Contacts and environment'</a> above and <a class="local">'Community setting'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Scabies in the institutional setting</strong> – Occurrences of scabies in institutional settings require prompt attention to minimize risk for transmission to other individuals. A rapid response is particularly important in the setting of crusted scabies. (See <a class="local">'Institutional setting'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Salavastru CM, Chosidow O, Boffa MJ, et al. European guideline for the management of scabies. J Eur Acad Dermatol Venereol 2017; 31:1248.</a></li><li><a class="nounderline abstract_t">Executive Committee of Guideline for the Diagnosis and Treatment of Scabies. Guideline for the diagnosis and treatment of scabies in Japan (third edition): Executive Committee of Guideline for the Diagnosis and Treatment of Scabies. J Dermatol 2017; 44:991.</a></li><li><a class="nounderline abstract_t">Heukelbach J, Feldmeier H. Scabies. Lancet 2006; 367:1767.</a></li><li><a class="nounderline abstract_t">Strong M, Johnstone P. Interventions for treating scabies. Cochrane Database Syst Rev 2007; :CD000320.</a></li><li><a class="nounderline abstract_t">Johnstone P, Strong M. Scabies. BMJ Clin Evid 2014; 2014.</a></li><li><a class="nounderline abstract_t">Currie BJ, McCarthy JS. Permethrin and ivermectin for scabies. N Engl J Med 2010; 362:717.</a></li><li><a class="nounderline abstract_t">Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.</a></li><li><a class="nounderline abstract_t">Chinazzo M, Desoubeaux G, Leducq S, et al. Prevalence of Nail Scabies: A French Prospective Multicenter Study. J Pediatr 2018; 197:154.</a></li><li class="breakAll">www.cdc.gov/parasites/scabies/index.html (Accessed on August 21, 2017).</li><li><a class="nounderline abstract_t">Veraldi S, De Micheli P, Schianchi R, Pontini P. A new treatment regimen with permethrin in scabies. G Ital Dermatol Venereol 2018; 153:491.</a></li><li><a class="nounderline abstract_t">Rosumeck S, Nast A, Dressler C. Ivermectin and permethrin for treating scabies. Cochrane Database Syst Rev 2018; 4:CD012994.</a></li><li><a class="nounderline abstract_t">Thadanipon K, Anothaisintawee T, Rattanasiri S, et al. Efficacy and safety of antiscabietic agents: A systematic review and network meta-analysis of randomized controlled trials. J Am Acad Dermatol 2019; 80:1435.</a></li><li><a class="nounderline abstract_t">Romani L, Whitfeld MJ, Koroivueta J, et al. Mass Drug Administration for Scabies Control in a Population with Endemic Disease. N Engl J Med 2015; 373:2305.</a></li><li class="breakAll">https://www.cdc.gov/parasites/scabies/health_professionals/meds.html (Accessed on September 29, 2021).</li><li><a class="nounderline abstract_t">Macotela-Ruíz E, Peña-González G. [The treatment of scabies with oral ivermectin]. Gac Med Mex 1993; 129:201.</a></li><li><a class="nounderline abstract_t">Twum-Danso NA. Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases. Filaria J 2003; 2 Suppl 1:S3.</a></li><li><a class="nounderline abstract_t">Gardon J, Gardon-Wendel N, Demanga-Ngangue, et al. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 1997; 350:18.</a></li><li><a class="nounderline abstract_t">Kerneuzet I, Blind E, Darrieux L, et al. Ivermectin-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. JAAD Case Rep 2018; 4:524.</a></li><li><a class="nounderline abstract_t">Barkwell R, Shields S. Deaths associated with ivermectin treatment of scabies. Lancet 1997; 349:1144.</a></li><li><a class="nounderline abstract_t">Coyne PE, Addiss DG. Deaths associated with ivermectin for scabies. Lancet 1997; 350:215.</a></li><li><a class="nounderline abstract_t">Diazgranados JA, Costa JL. Deaths after ivermectin treatment. Lancet 1997; 349:1698.</a></li><li><a class="nounderline abstract_t">Sunderkötter C, Feldmeier H, Fölster-Holst R, et al. S1 guidelines on the diagnosis and treatment of scabies - short version. J Dtsch Dermatol Ges 2016; 14:1155.</a></li><li><a class="nounderline abstract_t">Ly F, Caumes E, Ndaw CA, et al. Ivermectin versus benzyl benzoate applied once or twice to treat human scabies in Dakar, Senegal: a randomized controlled trial. Bull World Health Organ 2009; 87:424.</a></li><li><a class="nounderline abstract_t">Brooks PA, Grace RF. Ivermectin is better than benzyl benzoate for childhood scabies in developing countries. J Paediatr Child Health 2002; 38:401.</a></li><li><a class="nounderline abstract_t">Thomas C, Coates SJ, Engelman D, et al. Ectoparasites: Scabies. J Am Acad Dermatol 2020; 82:533.</a></li><li><a class="nounderline abstract_t">Pruksachatkunakorn C, Damrongsak M, Sinthupuan S. Sulfur for scabies outbreaks in orphanages. Pediatr Dermatol 2002; 19:448.</a></li><li><a class="nounderline abstract_t">Singalavanija S, Limpongsanurak W, Soponsakunkul S. A comparative study between 10 per cent sulfur ointment and 0.3 per cent gamma benzene hexachloride gel in the treatment of scabies in children. J Med Assoc Thai 2003; 86 Suppl 3:S531.</a></li><li><a class="nounderline abstract_t">Sharquie KE, Al-Rawi JR, Noaimi AA, Al-Hassany HM. Treatment of scabies using 8% and 10% topical sulfur ointment in different regimens of application. J Drugs Dermatol 2012; 11:357.</a></li><li class="breakAll">Sklice (ivermectin) lotion, 0.5%, for topical use. US FDA approved product information; Atlanta, GA: Arbor Pharmaceuticals; June 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202736s003lbl.pdf (Accessed on September 27, 2021).</li><li><a class="nounderline abstract_t">Chhaiya SB, Patel VJ, Dave JN, et al. Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies. Indian J Dermatol Venereol Leprol 2012; 78:605.</a></li><li><a class="nounderline abstract_t">Goldust M, Rezaee E. The efficacy of topical ivermectin versus malation 0.5% lotion for the treatment of scabies. J Dermatolog Treat 2013.</a></li><li><a class="nounderline abstract_t">Ahmad HM, Abdel-Azim ES, Abdel-Aziz RT. Clinical efficacy and safety of topical versus oral ivermectin in treatment of uncomplicated scabies. Dermatol Ther 2016; 29:58.</a></li><li class="breakAll">Natroba (spinosad) topical suspension. US FDA approved product information; Carmel, IN: ParaPRO; April 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022408s010lbl.pdf (Accessed on September 08, 2021).</li><li><a class="nounderline abstract_t">Seiler JC, Keech RC, Aker JL, et al. Spinosad at 0.9% in the treatment of scabies: Efficacy results from 2 multicenter, randomized, double-blind, vehicle-controlled studies. J Am Acad Dermatol 2022; 86:97.</a></li><li class="breakAll">Eurax (crotamiton USP) lotion/cream. US FDA approved product information; Princeton, NJ: Bristol Myers Squibb. www.accessdata.fda.gov/drugsatfda_docs/label/2003/06927slr030,09112slr021_eurax_lbl.pdf (Accessed on August 22, 2017).</li><li><a class="nounderline abstract_t">Pourhasan A, Goldust M, Rezaee E. Treatment of scabies, permethrin 5% cream vs. crotamiton 10% cream. Ann Parasitol 2013; 59:143.</a></li><li><a class="nounderline abstract_t">Marlière V, Roul S, Labrèze C, Taïeb A. Crusted (Norwegian) scabies induced by use of topical corticosteroids and treated successfully with ivermectin. J Pediatr 1999; 135:122.</a></li><li><a class="nounderline abstract_t">Corbett EL, Crossley I, Holton J, et al. Crusted ("Norwegian") scabies in a specialist HIV unit: successful use of ivermectin and failure to prevent nosocomial transmission. Genitourin Med 1996; 72:115.</a></li><li><a class="nounderline abstract_t">Taplin D, Meinking TL. Treatment of HIV-related scabies with emphasis on the efficacy of ivermectin. Semin Cutan Med Surg 1997; 16:235.</a></li><li><a class="nounderline abstract_t">Huffam SE, Currie BJ. Ivermectin for Sarcoptes scabiei hyperinfestation. Int J Infect Dis 1998; 2:152.</a></li><li><a class="nounderline abstract_t">Thomas C, Rehmus W, Chang AY. Treatment practices in the management of scabies in infants younger than two months. Pediatr Dermatol 2021; 38:431.</a></li><li><a class="nounderline abstract_t">Bécourt C, Marguet C, Balguerie X, Joly P. Treatment of scabies with oral ivermectin in 15 infants: a retrospective study on tolerance and efficacy. Br J Dermatol 2013; 169:931.</a></li><li><a class="nounderline abstract_t">Müllegger RR, Häring NS, Glatz M. Skin infections in pregnancy. Clin Dermatol 2016; 34:368.</a></li><li><a class="nounderline abstract_t">Chosidow O. Clinical practices. Scabies. N Engl J Med 2006; 354:1718.</a></li><li><a class="nounderline abstract_t">Johnston G, Sladden M. Scabies: diagnosis and treatment. BMJ 2005; 331:619.</a></li><li><a class="nounderline abstract_t">Chung SD, Wang KH, Huang CC, Lin HC. Scabies increased the risk of chronic kidney disease: a 5-year follow-up study. J Eur Acad Dermatol Venereol 2014; 28:286.</a></li><li><a class="nounderline abstract_t">Suh KS, Han SH, Lee KH, et al. Mites and burrows are frequently found in nodular scabies by dermoscopy and histopathology. J Am Acad Dermatol 2014; 71:1022.</a></li><li><a class="nounderline abstract_t">Karthikeyan K. Treatment of scabies: newer perspectives. Postgrad Med J 2005; 81:7.</a></li><li><a class="nounderline abstract_t">Mittal A, Garg A, Agarwal N, et al. Treatment of nodular scabies with topical tacrolimus. Indian Dermatol Online J 2013; 4:52.</a></li><li><a class="nounderline abstract_t">Almeida HL Jr. Treatment of steroid-resistant nodular scabies with topical pimecrolimus. J Am Acad Dermatol 2005; 53:357.</a></li><li><a class="nounderline abstract_t">Zawar V, Pawar M. Liquid nitrogen cryotherapy in the treatment of chronic, unresponsive nodular scabies. J Am Acad Dermatol 2017; 77:e43.</a></li><li><a class="nounderline abstract_t">Chambliss ML. Treating asymptomatic bodily contacts of patients with scabies. Arch Fam Med 2000; 9:473.</a></li><li><a class="nounderline abstract_t">FitzGerald D, Grainger RJ, Reid A. Interventions for preventing the spread of infestation in close contacts of people with scabies. Cochrane Database Syst Rev 2014; :CD009943.</a></li><li><a class="nounderline abstract_t">Stoff BK, Introcaso C, Kinlaw K, Swerlick RA. Expedited partner therapy for scabies: legal and ethical considerations. J Am Acad Dermatol 2013; 69:795.</a></li><li class="breakAll">https://www.cdc.gov/std/ept/default.htm (Accessed on December 11, 2020).</li><li class="breakAll">www.cdc.gov/parasites/scabies/health_professionals/institutions.html (Accessed on August 21, 2017).</li><li><a class="nounderline abstract_t">Lake SJ, Kaldor JM, Hardy M, et al. Mass Drug Administration for the Control of Scabies: A Systematic Review and Meta-analysis. Clin Infect Dis 2022; 75:959.</a></li></ol></div><div id="topicVersionRevision">Topic 114369 Version 10.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28639722" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : European guideline for the management of scabies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28561292" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Guideline for the diagnosis and treatment of scabies in Japan (third edition): Executive Committee of Guideline for the Diagnosis and Treatment of Scabies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16731272" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Scabies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17636630" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Interventions for treating scabies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25544114" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Scabies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20181973" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Permethrin and ivermectin for scabies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Sexually Transmitted Infections Treatment Guidelines, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29576324" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prevalence of Nail Scabies: A French Prospective Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29576324" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prevalence of Nail Scabies: A French Prospective Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27982546" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A new treatment regimen with permethrin in scabies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29608022" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Ivermectin and permethrin for treating scabies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30654070" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Efficacy and safety of antiscabietic agents: A systematic review and network meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26650152" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Mass Drug Administration for Scabies Control in a Population with Endemic Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26650152" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Mass Drug Administration for Scabies Control in a Population with Endemic Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7926408" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : [The treatment of scabies with oral ivermectin].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14975060" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9217715" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30023418" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Ivermectin-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9113017" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Deaths associated with ivermectin treatment of scabies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9250202" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Deaths associated with ivermectin for scabies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9186403" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Deaths after ivermectin treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27879074" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : S1 guidelines on the diagnosis and treatment of scabies - short version.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19565120" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Ivermectin versus benzyl benzoate applied once or twice to treat human scabies in Dakar, Senegal: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12174005" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Ivermectin is better than benzyl benzoate for childhood scabies in developing countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31310840" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Ectoparasites: Scabies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12383106" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Sulfur for scabies outbreaks in orphanages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14700144" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A comparative study between 10 per cent sulfur ointment and 0.3 per cent gamma benzene hexachloride gel in the treatment of scabies in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22395587" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Treatment of scabies using 8% and 10% topical sulfur ointment in different regimens of application.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22395587" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Treatment of scabies using 8% and 10% topical sulfur ointment in different regimens of application.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22960817" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23472617" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The efficacy of topical ivermectin versus malation 0.5% lotion for the treatment of scabies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26555785" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clinical efficacy and safety of topical versus oral ivermectin in treatment of uncomplicated scabies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26555785" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clinical efficacy and safety of topical versus oral ivermectin in treatment of uncomplicated scabies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34391812" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Spinosad at 0.9% in the treatment of scabies: Efficacy results from 2 multicenter, randomized, double-blind, vehicle-controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34391812" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Spinosad at 0.9% in the treatment of scabies: Efficacy results from 2 multicenter, randomized, double-blind, vehicle-controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24881286" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Treatment of scabies, permethrin 5% cream vs. crotamiton 10% cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10393619" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Crusted (Norwegian) scabies induced by use of topical corticosteroids and treated successfully with ivermectin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8698358" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Crusted ("Norwegian") scabies in a specialist HIV unit: successful use of ivermectin and failure to prevent nosocomial transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9300635" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Treatment of HIV-related scabies with emphasis on the efficacy of ivermectin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9531662" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Ivermectin for Sarcoptes scabiei hyperinfestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33486822" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Treatment practices in the management of scabies in infants younger than two months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23724970" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Treatment of scabies with oral ivermectin in 15 infants: a retrospective study on tolerance and efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27265075" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Skin infections in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625010" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Clinical practices. Scabies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16166133" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Scabies: diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23374101" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Scabies increased the risk of chronic kidney disease: a 5-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25437970" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Mites and burrows are frequently found in nodular scabies by dermoscopy and histopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15640423" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Treatment of scabies: newer perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23437425" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Treatment of nodular scabies with topical tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16021143" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Treatment of steroid-resistant nodular scabies with topical pimecrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28711102" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Liquid nitrogen cryotherapy in the treatment of chronic, unresponsive nodular scabies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10810954" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Treating asymptomatic bodily contacts of patients with scabies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24566946" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Interventions for preventing the spread of infestation in close contacts of people with scabies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24124808" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Expedited partner therapy for scabies: legal and ethical considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24124808" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Expedited partner therapy for scabies: legal and ethical considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24124808" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Expedited partner therapy for scabies: legal and ethical considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35088849" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Mass Drug Administration for the Control of Scabies: A Systematic Review and Meta-analysis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
